National Institute of Child Health and Human Development
Maternal-Fetal Medicine Units Network

Publications & Presentations
Progesterone Trial

Publications

1. Meis P, Klebanoff M, Thom E, Dombrowski M, Sibai S, Moawad A, Spong C, Hauth J, Miodovnik M, Varner M, Leveno K, Caritis S, Iams J, Wapner R, Conway D, OÆSullivan M, Carpenter M, Mercer B, Ramin S, Thorp J, Peaceman A, for the NICHD MFMU Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. The New England Journal of Medicine, 348: 2379-85, 2003.



2. Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O’Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Does progesterone treatment influence risk factors for recurrent preterm delivery? Obstetrics and Gynecology, 106(3): 557-561, 2005.



3. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O’Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S for the NICHD Maternal-Fetal Medicine Units Network. Progesterone for Prevention of Recurrent Preterm Birth: Impact of gestational age at previous delivery. American Journal of Obstetrics and Gynecology, 193(3): 1056-1060, 2005.



4. Sibai B, Meis PJ, Klebanoff M, Dombrowski MP, Weiner SJ, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O’Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S for the NICHD Maternal-Fetal Medicine Units Network. Plasma CRH measurement at 16-20 weeks’ gestation does not predict preterm delivery in women at high-risk for preterm delivery. American Journal of Obstetrics and Gynecology, 193(3): 1181-1186, 2005.



5. Klebanoff MA, Meis PJ, Dombrowski MP, Zhao Y, Moawad AH, Northen A, Sibai BM, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Leveno KJ, Miodovnik M, Conway D, Wapner RJ, Carpenter M, Mercer BM, Ramin SM, Thorp JM, Peaceman AM and National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Salivary progesterone and estriol among pregnant women treated with 17-a-hydroxyprogesterone caproate or placebo. American Journal of Obstetrics and Gynecology , 199: 506.e1 - 506.e7, 2008.

Presentations

1. Meis P, for the NICHD MFMU Network. Alpha hydroxyprogesterone caproate prevents recurrent preterm birth. Presented at the 23rd Annual Meeting of the Society for Maternal Fetal Medicine, San Francisco, CA, February 2003.



2. Meis P, for the NICHD MFMU Network. More than one previous preterm delivery and the risk of preterm birth in women treated with 17 alpha hydroxyprogesterone (17P). Presented at the 24th Annual Meeting of the Society for the Maternal Fetal Medicine, New Orleans, LA, February 2004.



3. Spong C. for the NICHD MFMU Network. Progesterone for prevention of recurrent Preterm birth: Impact of gestational age at prior delivery. Presented at the 25th Annual Meeting of the Society for Maternal-Fetal Medicine, Reno, NV, February 2005.



4. Sibai B. for the NICHD MFMU Network. Plasma CRH levels at 16-20 weeks do not predict preterm delivery in women at high-risk for preterm delivery. Presented at the 25th Annual Meeting of the Society for Maternal-Fetal Medicine, Reno, NV, February 2005.



5. Koontz G for the NICHD MFMU Network. Title: Does gestational age at randomization affect the efficacy of alpha Hydroxyprogesterone Caproate (17-OHCP) in preventing recurrent preterm delivery? Presented at the 26th Annual Meeting of the Society for Maternal-Fetal Medicine, Miami Beach, FL, January 2006.



6. Klebanoff, MA for the NICHD MFMU Network. Salivary progesterone and estriol concentrations at 16-20 weeks and risk of preterm birth. Presented at the Annual Meeting of the Society for Gynecological Investigation, Toronto, Canada, March 2006.



7. Klebanoff, M for the NICHD MFMU Network. Impact of 17 alpha hydroxyprogesterone caproate administration of salivary progesterone and estriol. Presented at the 27th Annual Meeting of the Society for Maternal-Fetal Medicine, San Francisco, CA, February 2007.



8. Smith, J for the NICHD MFMU Network. Treatment with 17-alpha hydroxyprogesterone caproate (17-OHP) reduces NICU Length of Stay (LOS) by improvement in gestational age at delivery. Presented at the 54th Annual Scientific Meeting for Society of Gynecologic Investigation, Reno, NV, March 2007.